Related references
Note: Only part of the references are listed.Population pharmacokinetics of clonazepam in saliva and plasma: Steps towards noninvasive pharmacokinetic studies in vulnerable populations
Matthijs D. Kruizinga et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Theoretical Performance of Nonlinear Mixed-Effect Models Incorporating Saliva as an Alternative Sampling Matrix for Therapeutic Drug Monitoring in Pediatrics: A Simulation Study
Matthijs D. Kruizinga et al.
THERAPEUTIC DRUG MONITORING (2021)
Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation
Yidan Sun et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)
Is Salivary Busulfan the Cause of Oral Mucositis and the Changes in Salivary Antioxidant Enzymes After Hematopoietic Cell Transplantation?
Fernanda de Paula Eduardo et al.
THERAPEUTIC DRUG MONITORING (2020)
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia
Craig Speziali et al.
LEUKEMIA & LYMPHOMA (2019)
Is Moxifloxacin a Treatment Option for Pancreatic Infections? A Pharmacometric Analysis of Serum and Pancreatic Juice
Sebastian G. Wicha et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants
Laura Hutchinson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Error measures in quantitative structure-retention relationships studies
Maryam Taraji et al.
JOURNAL OF CHROMATOGRAPHY A (2017)
Effect of Age and Allele Variants of CYP3A5, CYP3A4, and POR Genes on the Pharmacokinetics of Cyclosporin A in Pediatric Renal Transplant Recipients From Serbia
Mirjana Cvetkovic et al.
THERAPEUTIC DRUG MONITORING (2017)
Therapeutic salivary monitoring of IV busulfan in patients undergoing hematopoietic stem cell transplantation: a pilot study
L. M. Bezinelli et al.
BONE MARROW TRANSPLANTATION (2017)
Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram
Su-jin Rhee et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation
Xuemei Wu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2017)
Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee
Jeanne Palmer et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation
Boyoon Choi et al.
PHARMACOGENOMICS (2015)
Understanding Bland Altman analysis
Davide Giavarina
BIOCHEMIA MEDICA (2015)
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)
Jan H. Beumer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Jeannine S. McCune et al.
CLINICAL CANCER RESEARCH (2014)
Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics
M. H. ten Brink et al.
DRUG DISCOVERY TODAY (2014)
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
Edward A. Copelan et al.
BLOOD (2013)
Accurate Targeting of Daily Intravenous Busulfan with 8-Hour Blood Sampling in Hospitalized Adult Hematopoietic Cell Transplant Recipients
Rosa F. Yeh et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients
Sangmin Choe et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2012)
Standard Error of Empirical Bayes Estimate in NONMEM® VI
Dongwoo Kang et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2012)
Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children: The Results of a Population Pharmacokinetic Study From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation
Angelo Paci et al.
THERAPEUTIC DRUG MONITORING (2012)
Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models
Martin Bergstrand et al.
AAPS JOURNAL (2011)
Intravenous Busulfan-Cyclophosphamide as a Preparative Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Lymphoblastic Leukemia
Wei Tang et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Linearity and Stability of Intravenous Busulfan Pharmacokinetics and the Role of Glutathione in Busulfan Elimination
Shlomo Almog et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Therapeutic drug monitoring of busulfan in transplantation
J. A. Russell et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients
Brian P. Booth et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation
H Takama et al.
BONE MARROW TRANSPLANTATION (2006)
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
L Nguyen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children
M Rauh et al.
CLINICAL PHARMACOKINETICS (2006)
Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes
T Niwa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan plus cyclophosphamide for allogeneic bone marrow transplantation
JH Lee et al.
ANNALS OF HEMATOLOGY (2005)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
I. V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients
L Nguyen et al.
BONE MARROW TRANSPLANTATION (2004)
Circadian rhythm of salivary cortisol, 17α-hydroxyprogesterone, and progesterone in healthy children
M Gröschl et al.
CLINICAL CHEMISTRY (2003)
Population pharmacokinetics of oral busulfan in children
B Schiltmeyer et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
M Sandström et al.
BONE MARROW TRANSPLANTATION (2001)
Ways to fit a PK model with some data below the quantification limit
SL Beal
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin
T Gordi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Saliva and serum concentration of lamotrigine in patients with epilepsy
I Tsiropoulos et al.
THERAPEUTIC DRUG MONITORING (2000)
Acute safety and pharmacokinetics of intravenous busulfan when used with oval busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I study
BS Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)